INTRODUCTION

- Influenza and pneumococcal vaccination have proven to be cost-effective in numerous studies worldwide. However, studies are mostly health economic models based on short-term effect data for hospital-treated influenza and pneumonia and related short-term costs in selected populations. (Grennan & et al., 2015; Porchia & et al., 2017; Kuhlmann & von der Schulenburg, 2017)
- In our study we adopt a wider perspective on morbidity effects and health care utilization, using real world claims data of a major health insurance funds (AOK PLUS) in Thuringia.
- Research question: Do vaccinated patients show lower degree of health care utilization, costs and sick leave days than non-vaccinated patients?
- The results for the Thuringian study population will be extrapolated to the German population.

METHODS

Study design:
- Retrospective case-control-study
- Study population: individuals ≥ 60 years, living in Thuringia, insured with AOK PLUS; (covering intervention group): insured persons vaccinated against pneumococcal (pnc) and/or influenza (flu) infection in 2014; controls (control group) are insured persons without pneumococcal vaccination in 2008-2017 and without influenza vaccination in 2012-2017
- Follow-ups in 2015, 2016, 2017 and 2018 (see Fig. 1)

Statistical analysis:
- Mean differences and differences in mean changes in outcome measures (see below) between cases and controls
- Adequate adjustment methods (multiple regression analysis, propensity score matching); relevant variables/confounders are: age, gender, nationality, comorbidity (as risk factors for mortality and as risk factors for future costs), earlier severe infections like invasive pneumococcal disease or sepsis, participation in disease management programs for COPD/asthma or coronary heart diseases.

RESULTS

Identification of cases and controls by vaccination claims
- Codes for pneumococcal vaccination: 89118 A, 89118 B, 89119, 89120, 89120 R, 89964, 89964 A, 89964 E, 89964 B, 89964 I, 89964 K
- Codes for influenza vaccination: 89111, 89112, 89112 N, 89960, 89960 A, 89960 E, 89960 B, 89960 I, 89960 K

Data sources for the estimation of expected cases (see Fig. 2)
- Number of vaccinated patients ≥ 60 years of age in Thuringia in 2014 reported by the central database of health insurance claims of the Associations of Statutory Health Insurance Physicians (ASHIPs) in Germany (KHL 2017)
- Assumption, that at least 40% of the Thuringian population are insured with the AOK PLUS
- 300,000 of the AOK PLUS insured individuals living in Thuringia are older than 60 years

Outcome measures:
- Disease burden: Influenza, respiratory infections, pneumonia, invasive pneumococcal disease (IPD), sepsis and a combination of influenza, IPD, respiratory infection and superinfections with sepsis
- Health care utilization and cost: consultations at physicians (general practitioners and specialists), drug prescriptions, hospital care, remedies prescriptions, therapeutic aids, inpatient and outpatient rehabilitation, home care, institutional long-term nursing care, sick leave days

CONCLUSION

- Real-world data on the short- and middle-term effects of vaccinations on health care utilization and costs in the campaign region of Thuringia can serve as a valid data source for local and national stakeholders and will help to derive valuable arguments for their future actions regarding vaccination.
- The study results may also serve as future input parameters for health economic models estimating the cost-effectiveness-evaluation of influenza and pneumococcal vaccinations.

REFERENCES


Contact
Dr. Antje Freytag, Senior Health Economist, Research Coordinator, Institute of General Practice and Family Medicine, Jena University Hospital, Bachstraße 18, 07743 Jena, antje.freytag@med.uni-jena.de,
Tel.: ++49 36 41 9 39 58 11, Fax: +49 3641 9 39 58 02